Comparing Iqvia (IQV) and BIOQUAL (BIOQ)

Iqvia (NYSE:IQV) and BIOQUAL (OTCMKTS:BIOQ) are both business services companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.

Risk & Volatility

Iqvia has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Comparatively, BIOQUAL has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500.

Profitability

This table compares Iqvia and BIOQUAL’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Iqvia 12.29% 13.69% 4.79%
BIOQUAL 9.51% N/A N/A

Institutional & Insider Ownership

91.4% of Iqvia shares are held by institutional investors. 6.0% of Iqvia shares are held by company insiders. Comparatively, 39.2% of BIOQUAL shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and price targets for Iqvia and BIOQUAL, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Iqvia 0 4 13 1 2.83
BIOQUAL 0 0 0 0 N/A

Iqvia presently has a consensus target price of $131.06, indicating a potential upside of 5.55%. Given Iqvia’s higher possible upside, analysts plainly believe Iqvia is more favorable than BIOQUAL.

Valuation & Earnings

This table compares Iqvia and BIOQUAL’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Iqvia $9.74 billion 2.58 $1.31 billion $4.36 28.48
BIOQUAL $35.88 million 0.87 $3.66 million N/A N/A

Iqvia has higher revenue and earnings than BIOQUAL.

Dividends

BIOQUAL pays an annual dividend of $0.60 per share and has a dividend yield of 1.7%. Iqvia does not pay a dividend.

Summary

Iqvia beats BIOQUAL on 12 of the 14 factors compared between the two stocks.

Iqvia Company Profile

IQVIA Holdings Inc. provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order to life science companies, and investment and financial sectors that deal with life science companies; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level to pharmaceutical sales organizations. The Research & Development Solutions segment offers biopharmaceutical development services comprising project management and clinical monitoring, clinical trial support, and strategic planning and design services, as well as clinical trial, genomic, and bioanalytical laboratory services. The Integrated Engagement Services segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. The company serves pharmaceutical, biotechnology, device and diagnostic, and healthcare companies. IQVIA Holdings Inc. has a strategic alliance with MuleSoft, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

BIOQUAL Company Profile

Bioqual, Inc. provides research, development, consulting, and testing/assay services to commercial clients and government laboratories in the United States. The company provides research services in the areas of cancer, AIDS, hepatitis, influenza, immunology, transgenic, contraception, breeding and development of genetically defined animals, and neurobiology and behavior, as well as zika, dengue, malaria, respiratory syncytial virus, and other infectious diseases. Its services also include sample processing, virus stock generation, infectious virus quantitation, virus neutralization assays, hemagglutination inhibition assays, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition, the company provides in-vivo animal model related services. Bioqual, Inc. was founded in 1981 and is headquartered in Rockville, Maryland.

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply